US visitors, please note: This website contains information on the PROGENSA® PCA3 Assay which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or applicable in the USA. View details on US FDA approval for PROGENSA® PCA3 Assay.
Prostate cancer that does not respond anymore to hormone therapy. This is characterised by a rise in prostate specific antigen (PSA) levels during hormone therapy